Nevertheless, and regardless of the fact that HuR levels were not predictive of OS, neither in patients receiving gemcitabine nor in those receiving 5-FU, the data shown above are, generally, compatible with a treatment approach where gemcitabine treatment heralds radiation, leading to an augmentation of pancreatic cancer cell killing. The gene discussed is ELAVL1; the disease is pancreatic neoplasm.